BR112017008867A2 - inibidores de proteína quinases - Google Patents

inibidores de proteína quinases

Info

Publication number
BR112017008867A2
BR112017008867A2 BR112017008867A BR112017008867A BR112017008867A2 BR 112017008867 A2 BR112017008867 A2 BR 112017008867A2 BR 112017008867 A BR112017008867 A BR 112017008867A BR 112017008867 A BR112017008867 A BR 112017008867A BR 112017008867 A2 BR112017008867 A2 BR 112017008867A2
Authority
BR
Brazil
Prior art keywords
protein kinase
kinase inhibitors
methods
pharmaceutical compositions
relates
Prior art date
Application number
BR112017008867A
Other languages
English (en)
Inventor
Yu Chuiliang
Ding Jian
Sun Jing
LINGHU Li
Jiang Lihua
Yang Lijun
Chen Ling
Meng Linghua
Geng Meiyu
Liu Qihong
Tan Rui
Li Tongshuang
Wang Weibo
Wang Xianlong
Zhao Xingdong
Lui Yanxin
Rong Yue
Zhou Zuwen
Original Assignee
Chongqing Fochon Pharmaceutical Co Ltd
Shanghai Fochon Pharmaceutical Co Ltd
Shanghai Inst Materia Medica Cas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Fochon Pharmaceutical Co Ltd, Shanghai Fochon Pharmaceutical Co Ltd, Shanghai Inst Materia Medica Cas filed Critical Chongqing Fochon Pharmaceutical Co Ltd
Publication of BR112017008867A2 publication Critical patent/BR112017008867A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

a presente invenção refere-se a alguns inibidores da pi3k, composições farmacêuticas dos mesmos, e métodos de uso para os mesmos.
BR112017008867A 2014-11-01 2015-11-01 inibidores de proteína quinases BR112017008867A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462073993P 2014-11-01 2014-11-01
PCT/CN2015/093551 WO2016066142A1 (en) 2014-11-01 2015-11-01 Certain protein kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112017008867A2 true BR112017008867A2 (pt) 2017-12-26

Family

ID=55856639

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008867A BR112017008867A2 (pt) 2014-11-01 2015-11-01 inibidores de proteína quinases

Country Status (9)

Country Link
US (1) US10328060B2 (pt)
EP (1) EP3224248B1 (pt)
JP (1) JP6831324B2 (pt)
CN (1) CN107207441B (pt)
AU (1) AU2015341186B2 (pt)
BR (1) BR112017008867A2 (pt)
CA (1) CA2966252C (pt)
ES (1) ES2879809T3 (pt)
WO (1) WO2016066142A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3164400A1 (en) * 2014-07-04 2017-05-10 Lupin Limited Quinolizinone derivatives as pi3k inhibitors
WO2017103825A1 (en) 2015-12-18 2017-06-22 Lupin Limited Quinolizinone derivatives as pi3k inhibitors
CA3178569A1 (en) * 2020-05-16 2021-11-25 Zuwen ZHOU Compounds as protein kinase inhibitors
WO2022228387A1 (en) * 2021-04-26 2022-11-03 Fochon Biosciences, Ltd. Compounds as parp inhibitors
WO2023078401A1 (en) * 2021-11-05 2023-05-11 Fochon Biosciences, Ltd. Compounds as protein kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
AU2007323836B2 (en) * 2006-11-13 2013-04-18 Icos Corporation Thienopyrimidinones for treatment of inflammatory disorders and cancers
WO2008153947A2 (en) 2007-06-07 2008-12-18 Amgen Inc. Heterocyclic compounds as raf kinase modulators
TW201602113A (zh) 2009-06-29 2016-01-16 英塞特公司 作為ｐｉ３ｋ抑制劑之嘧啶酮
CA2796967C (en) 2010-05-04 2015-12-01 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
WO2013149362A1 (en) 2012-04-06 2013-10-10 Glaxosmithkline Llc 1-(dihydronaphthalenyl)pyridones as melanin-concentrating hormone receptor 1 antagonists
EP3164400A1 (en) * 2014-07-04 2017-05-10 Lupin Limited Quinolizinone derivatives as pi3k inhibitors

Also Published As

Publication number Publication date
AU2015341186B2 (en) 2019-11-14
CN107207441A (zh) 2017-09-26
JP2017533232A (ja) 2017-11-09
EP3224248A1 (en) 2017-10-04
CN107207441B (zh) 2020-11-24
CA2966252A1 (en) 2016-05-06
CA2966252C (en) 2023-10-24
JP6831324B2 (ja) 2021-02-17
EP3224248A4 (en) 2018-08-08
US20180036293A1 (en) 2018-02-08
EP3224248B1 (en) 2021-05-05
WO2016066142A1 (en) 2016-05-06
ES2879809T3 (es) 2021-11-23
AU2015341186A1 (en) 2017-06-08
US10328060B2 (en) 2019-06-25

Similar Documents

Publication Publication Date Title
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
BR112018005779A2 (pt) repressores de htt e usos dos mesmos
BR112018067408A2 (pt) formas sólidas de um inibidor de acc de tienopirimidinadiona e métodos para a produção das mesmas
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
EA201691582A1 (ru) Новые фармацевтические препараты
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
BR112016020618A2 (pt) oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
BR112015023760A2 (pt) compostos e composições terapêuticas
BR112017008714A2 (pt) inibidores de bromodomínio
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
EA201790785A1 (ru) Производные тетрагидроизохинолина
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
DK3350163T3 (da) Mono- eller disubstituerede indolderivater som hæmmere af denguevirusreplikation
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
BR112018008103A2 (pt) análogos de celastrol
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B25E Requested change of name of applicant rejected

Owner name: SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) ; CHONGQING FOCHON PHARMACEUTICAL CO., LTD (CN) ; SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO 870230082520 DE18/09/2023 DEVIDO AO DESPACHO PUBLICADO NA RPI 2761 DE 05/12/2023.

B25H Request for change of headquarter rejected

Owner name: SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) ; CHONGQING FOCHON PHARMACEUTICAL CO., LTD (CN) ; SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE SEDE CONTIDO NA PETICAO 870230082520 DE18/09/2023 DEVIDO AO DESPACHO PUBLICADO NA RPI 2761 DE 05/12/2023.